The role of tadalafil and sildenafil in reducing the risk of cardiovascular outcomes

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Sildenafil and tadalafil are selective PDE5 inhibitors for the treatment of erectile dysfunction (ED) that have vasodilatory properties mediated through NO and cGMP via smooth muscle relaxation. PDE5 inhibitors are approved for the treatment of ED, but only tadalafil is approved for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia. The association between ED, LUTS, and cardiovascular disease (CVD) has been established. Due to the expression of PDE5 in the cardiovascular system, potential mechanisms of PDE5 inhibitors include improvement of endothelial function, vasodilation with modest reductions in BP and afterload, direct myocardial protection, and anti-inflammatory and antiplatelet effects, which support the beneficial effects of PDE5 inhibitors in CVD. In experimental models, PDE5 inhibitors reduced myocardial ischemic reperfusion injury and arrhythmia, confirming their cardioprotective effect. Early clinical trials examined the effect of PDE5 inhibitors in patients with concomitant diabetes mellitus and showed a reduction in the incidence of myocardial infarction and mortality. Recent large cohort studies examined the long-term effects of PDE5 inhibitors on the risk of CVD and cardiovascular events. Two studies showed a significant reduction in the risk of MACE with tadalafil therapy by 19% (OR=0,81) and the risk of MACE/venous thromboembolism by 41% (OR=0,59). In a new study, the use of sildenafil and tadalafil led to a 34% and 44% reduction in the risk of mortality (OR=0,76 and OR=0,66), as well as a significant reduction in the risk of myocardial infarction, stroke, venous thromboembolism and even dementia in patients with ED and LUTS, with tadalafil having an advantage over sildenafil. According to the results of a meta-analysis of 16 studies, PDE5 inhibitors reduced the risk of MACE by 22% (OR=0,78) and the risk of overall mortality by 30% (OR=0,70).

Thus, new data on PDE-5 inhibitors were obtained, confirming not only the safety of the cardiovascular system, but also showing the presence of important cardioprotective properties.

全文:

受限制的访问

作者简介

Marina Leonova

Interregional public organization Association of Clinical Pharmacologists (Moscow branch)

编辑信件的主要联系方式.
Email: anti23@mail.ru
ORCID iD: 0000-0001-8228-1114
SPIN 代码: 3281-7884

Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Natural Sciences, Member of the Interregional Public Organization of the Association of Clinical Pharmacologists (Moscow Branch)

俄罗斯联邦, Moscow

参考

  1. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol. 2003;92(9A):19–25. https://dx.doi.org/10.1016/s0002-9149(03)00828-2
  2. Uckert S., Küthe A., Stief C.G., Jonas U. Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. W J Urol. 2001;19(1):14–22. https://dx.doi.org/10.1007/pl00007090
  3. Curran M., Keating G. Tadalafil. Drugs. 2003;63(20):2203–12. https://dx.doi.org/10.2165/00003495-200363200-00004
  4. Setter S.M., Iltz J.L., Fincham J.E., et al. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother. 2005;39(7–8):1286–95. https://dx.doi.org/10.1345/aph.1E487
  5. Andersson K.E. PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol. 2018;175(13):2554–65. https://dx.doi.org/10.1111/bph.14205
  6. Solomon H., Man J.W., Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart. 2003;89(3):251–3. https://dx.doi.org/10.1136/heart.89.3.251
  7. Jackson G. Erectile dysfunction and cardiovascular disease. Arab J Urol. 2013;11(3):212–6. https://dx.doi.org/10.1016/j.aju.2013.03.003
  8. Dong J.Y., Zhang Y.H., Qin L.Q. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58(13):1378–85. https://dx.doi.org/10.1016/j.jacc.2011.06.024
  9. Vlachopoulos C.V., Terentes-Printzios D.G., Ioakeimidis N.K., et al. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013;6(1):99–109. https://dx.doi.org/10.1161/CIRCOUTCOMES.112.966903
  10. Russo G.I., Castelli T., Privitera S., et al. Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptoms. BJU Int. 2015;116(5):791–6. https://dx.doi.org/10.1111/bju.13053
  11. Lee B., Lee S.W., Kang H.R., et al. Relationship between lower urinary tract symptoms and cardiovascular risk scores including Framingham risk score and ACC/AHA risk score. Neurourol Urodyn. 2018;37(1):426-33. https://dx.doi.org/10.1002/nau.23320
  12. Stasch J.P., Pacher P., Evgenov O.V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263–73. https://dx.doi.org/10.1161/CIRCULATIONAHA.110.981738
  13. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb Haemost. 2012;10(2):167–76. https://dx.doi.org/10.1111/j.1538-7836.2011.04576.x
  14. Rondina M.T., Weyrich A.S. Targeting phosphodiesterases in anti-platelet therapy. HandbExp. Pharmacol. 2012;(210):225–38. https://dx.doi.org/10.1007/978-3-642-29423-5_9
  15. Bajraktari G., Burhenne J., Bugert P., et al. Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. Biochem Pharmacol. 2017;145:54–63. https://dx.doi.org/10.1016/j.bcp.2017.08.026
  16. Kim G.E., Kass D.A. Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease. Handb Exp Pharmacol. 2017;243:249–69. https://dx.doi.org/10.1007/164_2016_82
  17. Blum A. Treating heart failure with sildenafil. Congest. Heart Fail. 2009;15(4):181–5. https://dx.doi.org/10.1111/j.1751-7133.2008.00026.x
  18. Ravipati G., McClung J.A., Aronow W.S., et al. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev. 2007;15(2):76–86. https://dx.doi.org/10.1097/01.crd.0000233904.77128.49
  19. Hutchings D.C., Anderson S.G., Caldwell J.L., Trafford A.W. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 2018;104(15):1244–50. https://dx.doi.org/10.1136/heartjnl-2017-312865
  20. Anderson S.G., Hutchings D.C., Woodward M., et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016; 102(21):1750–6. https://dx.doi.org/10.1136/heartjnl-2015-309223
  21. Giannetta E., Feola T., Gianfrilli D., et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med. 2014;12:185. https://dx.doi.org/10.1186/s12916-014-0185-3
  22. Andersson D.P., Trolle Lagerros Y., Grotta A., et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017;103(16):1264–70. https://dx.doi.org/10.1136/heartjnl-2016-310746
  23. Vestergaard N., Søgaard P., Torp-Pedersen C., Aasbjerg K. Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: a nationwide cohort study. Eur J Prev Cardiol. 2017;24(14):1498–505. https://dx.doi.org/10.1177/2047487317718082
  24. Kloner R.A., Stanek E., Desai K., et al. The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction. Clin Cardiol. 2024;47(2):e24234. https://dx.doi.org/10.1002/clc.24234
  25. Goberdhan S., Blachman-Braun R., Nackeeran S., et al. Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms? World J Urol. 2022;40(7):1799–803. https://dx.doi.org/10.1007/s00345-022-04005-3
  26. Jehle D.V.K., Sunesra R., Uddin H., et al. Benefits of tadalafil and sildenafil on mortality, cardiovascular disease, and dementia. Am J.Med. 2024:S0002-9343(24)00705-8. https://dx.doi.org/10.1016/j.amjmed.2024.10.039
  27. El-Bakly W., Wagdy O., Sobhy A., et al. The efficacy and underlying mechanism of phosphodiesterase- 5 inhibitors in preventing cognitive impairment and Alzheimer pathology: a systematic review of animal studies. Behav Brain Res. 2019;372:112004. https://dx.doi.org/10.1016/j.bbr.2019.112004
  28. Choi J.B., Cho K.J., Kim J.C., et al. The effect of daily low dose tadalafil on cerebral perfusion and cognition in patients with erectile dysfunction and mild cognitive impairment. Clin. Psychopharmacol. Neurosci. 2019;17(3):432–7. https://dx.doi.org/10.9758/cpn.2019.17.3.432
  29. Urios A., Ordono F., Garcia-Garcia R., et al. Tadalafil treatment improves inflammation, cognitive function, and mismatch negativity of patients with low urinary tract symptoms and erectile dysfunction. Sci. Rep. 2019;9(1):17119. https://dx.doi.org/10.1038/s41598-019-53136-y
  30. Pauls M.M.H., Binnie L.R., Benjamin P., et al. The PASTIS trial: testing tadalafil for possible use in vascular cognitive impairment. Alzheimers Dement. 2022;18(12):2393–402. https://dx.doi.org/10.1002/alz.12559
  31. Hainsworth A.H., Arancio O., Elahi F.M., et al. PDE5 inhibitor drugs for use in dementia. Alzheimers Dement (N.Y.). 2023;9(3):e12412. https://dx.doi.org/10.1002/trc2.12412
  32. Soulaidopoulos S., Terentes-Printzios D., Ioakeimidis N., et al. Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2024;10(5):403–12. https://dx.doi.org/10.1093/ehjcvp/pvae029
  33. Zhang J., Li X., Yang B., et al. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. World J Urol. 2019;37(1):143–53. https://dx.doi.org/10.1007/s00345-018-2370-z
  34. Yan H., Zong H., Cui Y., et al. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1539–45. https://dx.doi.org/10.1111/jsm.12499
  35. Tan P., Liu L., Wei S., et al. The effect of oral phosphodiesterase-5 inhibitors on sperm parameters: a meta-analysis and systematic review. Urology. 2017;105:54–61. https://dx.doi.org/10.1016/j.urology.2017.02.032
  36. Kloner R.A., Burnett A.L., Miner M., et al. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health. J Sex Med. 2024;21(2):90–116. https://dx.doi.org/10.1093/jsxmed/ qdad163

补充文件

附件文件
动作
1. JATS XML
下载
2. Figure 1. Schematic of the mechanism of action of phosphodiesterase type 5 inhibitors via the NO-cyclic guanosine monophosphate signaling pathway. Adapted from [4]

下载 (67KB)
索引源数据
3. Figure 2. Adjusted Kaplan-Meier survival curves showing MACE-free survival (A) or all-cause mortality (B) (24)

下载 (130KB)
索引源数据

版权所有 © Bionika Media, 2025